{"prompt": "['MC1575', '32', 'Amendment 2', '10.0', 'ADVERSE EVENT (AE) REPORTING AND MONITORING', 'The site principal investigator is responsible for reporting any/all serious adverse events to the', 'sponsor as described within the protocol, regardless of attribution to study agent or treatment', 'procedure.', 'The sponsor/sponsor-investigator is responsible for notifying FDA and all participating', 'investigators in a written safety report of any of the following:', 'Any suspected adverse reaction that is both serious and unexpected.', 'Any findings from laboratory animal or in vitro testing that suggest a significant risk for', 'human subjects, including reports of mutagenicity, teratogenicity, or carcinogenicity.', 'Any findings from epidemiological studies, pooled analysis of multiple studies, or', 'clinical studies, whether or not conducted under an IND and whether or not conducted by', 'the sponsor, that suggest a significant risk in humans exposed to the drug', 'Any clinically important increase in the rate of a serious suspected adverse reaction over', \"the rate stated in the protocol or Investigator's Brochure (IB).\", 'Summary of SAE Reporting for this study', '(please read entire section for specific instructions):', 'WHO:', 'WHAT form:', 'WHERE to send:', 'Mayo Sites - attach to MCCC', 'Pregnancy Reporting', 'Electronic SAE Reporting Form', 'All sites', 'Non Mayo sites - complete and', 'forward to', 'Mayo Clinic Cancer Center SAE Reporting Form:', 'Will automatically be sent to', 'Mayo Clinic', 'Sites', 'Definitions', 'Adverse Event', 'Any untoward medical occurrence associated with the use of a drug in humans, whether or', 'not considered drug related.', 'Suspected Adverse Reaction', 'Any adverse event for which there is a reasonable possibility that the drug caused the adverse', 'event.', 'Expedited Reporting', 'Events reported to sponsor within 24 hours, 5 days or 10 days of study team becoming aware', 'of the event.', 'Routine Reporting', 'Events reported to sponsor via case report forms', 'Events of Interest', 'Protocol Version Date:16Aug2018']['MC1575', '33', 'Amendment 2', 'Events that would not typically be considered to meet the criteria for expedited reporting, but', 'that for a specific protocol are being reported via expedited means in order to facilitate the', 'review of safety data (may be requested by the FDA or the sponsor).', 'Unanticipated Adverse Device Event (UADE)', 'Any serious adverse effect on health or safety or any life-threatening problem or death caused', 'by, or associated with, a device, if that effect, problem, or death was not previously identified', 'in nature, severity, or degree of incidence in the investigational plan or application (including', 'a supplementary plan or application), or any other unanticipated serious problem associated', 'with a device that relates to the rights, safety, or welfare of subjects', '10.1', 'Adverse Event Characteristics', 'CTCAE term (AE description) and grade: The descriptions and grading scales found', 'in the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version', '4.0 will be utilized for AE reporting. All appropriate treatment areas should have access', 'to a copy of the CTCAE version 4.0. A copy of the CTCAE version 4.0 can be', 'downloaded from the CTEP web site:', 'http://ctep.cancer.gov/protocolDevelopment/electronic applications/ctc.htm)', 'a. Identify the grade and severity of the event using the CTCAE version 4.0.', 'b. Determine whether the event is expected or unexpected (see Section 10.2).', 'c.', 'Determine if the adverse event is related to the study intervention (agent, treatment or', 'procedure) (see Section 10.3).', 'd. Determine whether the event must be reported as an expedited report. If yes,', 'determine the timeframe/mechanism (see Section 10.4).', 'e.', 'Determine if other reporting is required (see Section 10.5).', 'f.', 'Note: All AEs reported via expedited mechanisms must also be reported via the', 'routine data reporting mechanisms defined by the protocol (see Sections 10.6 and', '18.0).', 'NOTE: A severe AE is NOT the same as a serious AE, which is defined in Section 10.4.', '10.2', 'Expected vs. Unexpected Events', 'Expected events - are those described within the Section 15.0 of the protocol, the study', 'specific consent form, package insert (if applicable), and/or the investigator brochure, (if', 'an investigator brochure is not required, otherwise described in the general', 'investigational plan).', 'Unexpected adverse events or suspected adverse reactions are those not listed in Section', '15.0 of the protocol, the study specific consent form, package insert (if applicable), or in', 'the investigator brochure (or are not listed at the specificity or severity that has been', 'observed); if an investigator brochure is not required or available, is not consistent with', 'the risk information described in the general investigational plan.', 'Unexpected also refers to adverse events or suspected adverse reactions that are', 'mentioned in the investigator brochure as occurring with a class of drugs but have not', 'been observed with the drug under investigation.', 'An investigational agent/intervention might exacerbate the expected AEs associated with a', 'commercial agent. Therefore, if an expected AE (for the commercial agent) occurs with a', 'higher degree of severity or specificity, expedited reporting is required.', 'Protocol Version Date:16Aug2018']\n\n###\n\n", "completion": "END"}